SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Recruiting

Phase 1

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabSX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Sponsor:

Syntrix Biosystems, Inc.

Code:

NCT03161431

Conditions

Melanoma Stage III

Melanoma Stage IV

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SX-682

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-25. This information was provided to ClinicalTrials.gov by Syntrix Biosystems, Inc. on 2024-05-13.